Over the course of the past half a decade, the Teladoc Health (NYSE: TDOC) stock has been one of the biggest gainers in the healthcare sector.
While it is true that the stock had been a highly impressive performer even in the past 18 months, the situation has not been particularly great in 2021 so far. The Teladoc stock has declined by 11% in 2021 till date and at the same time, the S&P 500 index has gone up by 9%.
In 2020, the company’s revenues grew to $1.093 billion, which reflects a rise of 98% year on year. On the other hand, operating incoming without EBITDA came in at $126.8 million, which reflects a fourfold rise. Additionally, the number of subscribers soared to 51.8 million, which works out to a year-on-year rise of 41%. However, investors are under the impression that the company’s bottom line is going to fall off considerably in the coming period. That could be one of the reasons for the Teladoc stock’s poor performance in 2021.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.